3exo: Difference between revisions
No edit summary |
No edit summary |
||
| Line 30: | Line 30: | ||
</div> | </div> | ||
<div class="pdbe-citations 3exo" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 3exo" style="background-color:#fffaf0;"></div> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 12:22, 25 October 2017
Crystal structure of BACE1 bound to inhibitorCrystal structure of BACE1 bound to inhibitor
Structural highlights
Function[BACE1_HUMAN] Responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase.[1] [2] Evolutionary Conservation Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedA small molecule inhibitor of beta-secretase with a unique binding mode has been developed. Crystallographic determination of the enzyme-inhibitor complex shows the catalytic aspartate residues in the active site are not engaged in inhibitor binding. This unprecedented binding mode in the field of aspartyl protease inhibition is described. Identification of a small molecule beta-secretase inhibitor that binds without catalytic aspartate engagement.,Steele TG, Hills ID, Nomland AA, de Leon P, Allison T, McGaughey G, Colussi D, Tugusheva K, Haugabook SJ, Espeseth AS, Zuck P, Graham SL, Stachel SJ Bioorg Med Chem Lett. 2009 Jan 1;19(1):17-20. Epub 2008 Nov 13. PMID:19036583[3] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||||